YatırımMasasıYatırım Masası home
Climb Bio, Inc.
CLYMSEC EDGAR
Filing items
Item 8.01
Other events
Filing text
On August 13, 2026, Beijing Mabworks Biotech Co., Ltd. announced the dosing of the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China, which is being conducted in collaboration with Climb Bio, Inc.
Official document
Climb Bio, Inc., 8-KSEC EDGAR file no. 000119312526350596
View document